Natalia Buza, MD
Professor of PathologyCards
About
Research
Overview
Medical Research Interests
Gestational Trophoblastic Disease; Morphological and Microscopic Findings; Ovarian Neoplasms; Pathological Conditions, Anatomical; Uterine Cervical Neoplasms; Uterine Neoplasms; Vulvar Neoplasms
Publications
2024
Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Xu F, Hui P, Altwerger G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer: Updated survival and subgroup analyses. Gynecologic Oncology 2024, 190: s299-s301. DOI: 10.1016/j.ygyno.2024.07.449.Peer-Reviewed Original ResearchUtility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas
Greenman M, Bellone S, Hartwich T, Buza N, Santin A. Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas. Gynecologic Oncology Reports 2024, 56: 101524. PMID: 39435258, PMCID: PMC11492078, DOI: 10.1016/j.gore.2024.101524.Peer-Reviewed Original ResearchOvarian carcinomaNext generation sequencingPrimary uterine tumorsDiagnostically challenging casesOvarian tumorsPrimary tumorUterine tumorsEndometrial malignancyMetastatic tumorsAdjuvant treatmentClonal relationshipTargeted therapyUtilization of next generation sequencingTumor clonalityGeneration sequencingProtein expression profilesTumorChallenging casesImprove outcomesCarcinomaGold standardGenetic landscapeMalignancyClonalityExpression profilesTrastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2
Mutlu L, McNamara B, Bellone S, Manavella D, Demirkiran C, Greenman M, Verzosa M, Buza N, Hui P, Hartwich T, Harold J, Yang-Hartwich Y, Zipponi M, Altwerger G, Ratner E, Huang G, Clark M, Andikyan V, Azodi M, Schwartz P, Santin A. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Clinical & Experimental Metastasis 2024, 41: 765-775. PMID: 38909139, DOI: 10.1007/s10585-024-10297-z.Peer-Reviewed Original ResearchHigh-grade serous ovarian cancerClear cell carcinomaHER2-targeting antibody-drug conjugateAntibody-drug conjugatesT-DXdReceptor over-expressionTrastuzumab deruxtecanXenograft modelCell linesOvarian clear cell carcinomaOvarian cancer cell linesTumors overexpressing HER2Biologically aggressive tumorsFluorescence in situ hybridization assaySerous ovarian cancerEffective antibody-drug conjugatesIn vivo antitumor activityMouse xenograft modelMetastatic cell linesDS-8201aCancer cell linesAggressive tumorsHER2 expressionCell carcinomaOvarian cancerDiandric triploid partial mole versus digynic nonmolar triploidy: is morphological assessment sufficient for the diagnostic distinction?
Nagy A, Niu N, Sun T, Buza N, Hui P. Diandric triploid partial mole versus digynic nonmolar triploidy: is morphological assessment sufficient for the diagnostic distinction? Histopathology 2024, 85: 879-888. PMID: 39031756, DOI: 10.1111/his.15247.Peer-Reviewed Original ResearchPositive predictive valueTriploid gestationsPartial moleTrophoblastic hyperplasiaVillous sizeCistern formationHistological parametersPostmolar gestational trophoblastic neoplasiaTriploid partial molesGenotype-phenotype correlation studiesGestational trophoblastic neoplasiaPartial hydatidiform moleModerate interobserver agreementVillous populationsTrophoblastic neoplasiaGestational weeksHydatidiform moleClinical presentationPatient ageDigynic triploidyAbnormal histologyInterobserver agreementGestationSyncytiotrophoblastHistological assessmentRandomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMID: 39516558, PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-freePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatientsTargetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations.
Manrai P, McHenry A, Sun T, Santin A, Ratner E, Lin D, Elvin J, Hui P, Buza N. Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations. International Journal Of Gynecological Pathology 2024 PMID: 38914011, DOI: 10.1097/pgp.0000000000001050.Peer-Reviewed Original ResearchEndometrial carcinomaGynecologic malignanciesTyrosine kinase domainHER2-mutated non-small cell lung cancerTargeted anti-HER2 therapyNon-small cell lung cancerHigh-grade endometrioid adenocarcinomasFam-trastuzumab deruxtecanOvarian mucinous adenocarcinomaAnti-HER2 therapyAnti-HER2 drugsHER2 3+US Food and Drug AdministrationCell lung cancerEndometrial serous carcinomaSolid tumor typesStandard treatment recommendationsFood and Drug AdministrationFluorescence in situ hybridizationGynecological cancer typesEndometrial primaryMullerian originSerous carcinomaHER2 IHCEndometrioid adenocarcinomaRandomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)
Sheth S, Oh J, Bellone S, Siegel E, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim D, Iwasaki A, Levi A, Buza N, Hui P, Flaherty S, Schwartz P, Santin A. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147). Clinical Cancer Research 2024, 30: of1-of10. PMID: 38592381, DOI: 10.1158/1078-0432.ccr-23-3639.Peer-Reviewed Original ResearchConceptsRandomized phase II trialCD4/CD8 T cellsT cellsHPV clearanceArm BNo significant differenceClinical surveillanceRate of HPV clearanceSecondary outcomesPre-neoplastic cervical lesionsCervical intraepithelial neoplasiaT cell infiltrationT cell responsesSignificant differenceCIN3 patientsIntraepithelial neoplasiaArm ACervical lesionsImiquimod groupSurveillance armVaginal suppositoriesProspective trialsArm CHPV vaccinationImiquimodCorrection: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
Roque D, Siegel E, Buza N, Bellone S, Silasi D, Huang G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Reader J, Hui P, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin A. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. British Journal Of Cancer 2024, 130: 1073-1073. PMID: 38438590, PMCID: PMC10951353, DOI: 10.1038/s41416-024-02628-4.Peer-Reviewed Original ResearchNovel FOXL2 Mutation in an Ovarian Adult Granulosa Cell Tumor: Report of a Case With Diagnostic and Clinicopathologic Implications
Nagy A, Niu N, Ratner E, Hui P, Buza N. Novel FOXL2 Mutation in an Ovarian Adult Granulosa Cell Tumor: Report of a Case With Diagnostic and Clinicopathologic Implications. International Journal Of Gynecological Pathology 2024, 43: 631-636. PMID: 38426544, DOI: 10.1097/pgp.0000000000001024.Peer-Reviewed Original ResearchAdult granulosa cell tumorGranulosa cell tumorsOvarian sex cord-stromal tumorsSex cord-stromal tumorsCord-stromal tumorsCell tumorsFOXL2 mutationMutation c.Fibromatous stromaMalignant ovarian sex cord-stromal tumorAdjuvant vaginal cuff brachytherapyOvarian adult granulosa cell tumorsBilateral salpingo-oophorectomyRight ovarian massVaginal cuff brachytherapyAtypical endometrial hyperplasiaSuperficial myometrial invasionRoutine molecular testingUniform tumor cellsEndometrioid endometrial adenocarcinomaNested growth patternPoint mutation c.Months follow-upSalpingo-oophorectomyTotal hysterectomy
2023
Ovarian Leydig Cell Tumor Associated with Recurrent Torsion and Virilization in an Adolescent Patient
Roth L, Smith A, Buza N, Coons B, Stitelman D, Vash-Margita A. Ovarian Leydig Cell Tumor Associated with Recurrent Torsion and Virilization in an Adolescent Patient. Journal Of Pediatric And Adolescent Gynecology 2023, 37: 217-219. PMID: 38110028, DOI: 10.1016/j.jpag.2023.11.014.Peer-Reviewed Original ResearchPolycystic ovarian syndromeOvarian tumorsCell tumorsRecurrent ovarian torsionAbnormal uterine bleedingPost-menopausal womenLeydig cell tumorUterine bleedingOvarian syndromeOvarian torsionYounger patientsOvarian functionOvarian hilumAdolescent patientsNodular proliferationSecrete androgensTumor AssociatedRecurrent torsionPrimary amenorrheaCurrent recommendationsReinke crystalsTumorsLeydig cellsIncidence increasesVirilization
Clinical Trials
Current Trials
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer
HIC ID2000023639RoleSub InvestigatorPrimary Completion Date06/01/2026Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
As a pathologist specializing in gynecologic and breast cancers and diseases, Natalia Buza, MD, rarely sees the patients she spends many hours thinking about; her work is done not in an exam room, but behind a high-powered microscope. This doesn’t make her patients any less real, however. Dr. Buza explains that she became a pathologist because “it’s an exciting discipline and so important for patient care.”
Working closely with gynecologic cancer doctors, Dr. Buza examines samples of patients’ tissue taken for a biopsy to look for signs of endometrial, ovarian and cervical cancers. Once a cancer has been identified, she continues her examination of the cells, specifying the tumor subtype and looking for specific markers at the protein and genetic level that could help the patient’s physician create a personalized cancer treatment plan. Also, she notes, “I do a lot of collaborative research and studies.” For example, she and other colleagues recently investigated the possibility of using targeted anti-HER2 therapy in certain endometrial cancers.
Dr. Buza is a professor of Pathology and director of the Center for Excellence in Women’s Health Pathology at Yale School of Medicine.
Clinical Specialties
Pathology; Anatomic Pathology; Gynecological Pathology
News & Links
News
- April 15, 2024
Genetic Analysis of Rare, Often Deadly Cervical Cancer Uncovers Potential Treatments
- April 09, 2024
Topical Shows Promise in Treating Precancerous Cervical Condition
- November 07, 2023
Yale Diagnostic Pathology Annual CME Review held in NYC
- July 07, 2023Source: Medicine
Bibliometric and Visualized Analysis of Highly Cited Articles on Immunotherapy for Endometrial Cancer
Get In Touch
Contacts
Appointment Number
Clinical Inquiry Number
Clinic Fax Number
Locations
Department of Pathology
Academic Office
Brady Memorial Laboratory
310 Cedar Street, Wing Lauder Hall, Fl 2nd, Ste LH 219B
New Haven, CT 06510
Fax
203.737.1064Clinical Inquiry
203.737.5292Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
Events
Jun 202514-16Multiple Days
- EveryoneMulti-session EventPei Hui, PhD, MD - Krasimira Rozenova - Natalia Buza, MD - Deyin Xing, MD, PhD